Late-onset multiple acyl-CoA dehydrogenase deficiency: an insidious presentation.


Journal

BMJ case reports
ISSN: 1757-790X
Titre abrégé: BMJ Case Rep
Pays: England
ID NLM: 101526291

Informations de publication

Date de publication:
22 May 2023
Historique:
pmc-release: 22 05 2025
medline: 24 5 2023
pubmed: 23 5 2023
entrez: 22 5 2023
Statut: epublish

Résumé

Multiple acyl-CoA dehydrogenase deficiency (MADD) is a rare inborn error of metabolism that results in impairment of mitochondrial β-oxidation of fatty acids. It is inherited in an autosomal recessive manner and impairs electron transfer in the electron transport chain. The clinical manifestations of MADD are highly variable and include exercise intolerance, myopathy, cardiomyopathy, encephalopathy, coma and death. Early-onset MADD is often associated with a high mortality with significant number of patients presenting with severe metabolic acidosis, non-ketotic hypoglycaemia and/or hyperammonaemic presentations. While late-onset MADD is suggested to have a lower mortality, the severe encephalopathic presentations may well be under-reported as a diagnosis of MADD may not be considered.MADD is treatable with riboflavin and appropriate nutrition with a focus on prevention and early management of metabolic decompensation. The neonatal phenotype differs significantly from late-onset MADD, where diagnosis may be delayed due to heterogeneity in clinical features, atypical presentation and confounding comorbidities, together with lower awareness among physicians.This report describes a woman in her 30s who presented with acute-onset ataxia, confusion and hyperammonaemic encephalopathy requiring intubation. Subsequent biochemical investigation revealed a diagnosis of MADD. At present, there are no national guidelines in Australia for the management of MADD. This case highlights the investigation and treatment of late-onset MADD.

Identifiants

pubmed: 37217231
pii: 16/5/e252668
doi: 10.1136/bcr-2022-252668
pmc: PMC10230867
pii:
doi:

Substances chimiques

Electron-Transferring Flavoproteins 0
Riboflavin TLM2976OFR
Acyl-CoA Dehydrogenase EC 1.3.8.7

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© BMJ Publishing Group Limited 2023. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Naini Nishita Rao (NN)

Department of Endocrinology and Diabetes, Royal Perth Hospital, Perth, Western Australia, Australia n.nishita.rao@gmail.com.
School of Medicine, The University of Western Australia, Perth, Western Australia, Australia.

Kharis Burns (K)

Department of Endocrinology and Diabetes, Royal Perth Hospital, Perth, Western Australia, Australia.
School of Medicine, The University of Western Australia, Perth, Western Australia, Australia.

Catherine Manolikos (C)

Department of Endocrinology and Diabetes, Royal Perth Hospital, Perth, Western Australia, Australia.
Department of Dietetics and Nutrition, Royal Perth Hospital, Perth, Western Australia, Australia.

Samantha Hodge (S)

Department of Endocrinology and Diabetes, Royal Perth Hospital, Perth, Western Australia, Australia.
Department of Dietetics and Nutrition, Royal Perth Hospital, Perth, Western Australia, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH